SCHEDULE 13G 0000919185 XXXXXXXX LIVE Ordinary Shares, par value NIS 0.10 per share 06/30/2025 0001498403 BioLineRx Ltd. 09071M304 2 HAMA-AYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN L3 7177871 Rule 13d-1(b) Highbridge Capital Management, LLC DE 172950600.00 0.00 172950600.00 0.00 172950600.00 N 7.2 IA OO The 172,950,600 Ordinary Shares (as defined in Item 2(a)) reported herein are represented by 288,251 ADSs (as defined in Item 2(a)) issuable upon exercise of warrants. BioLineRx Ltd. 2 HAMA-AYAN STREET, MODI-IN, Israel 7177871 This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the ordinary shares, par value NIS 0.10 per share ("Ordinary Shares"), of BioLineRx Ltd., an Israeli corporation (the "Issuer"), issuable upon exercise of warrants directly held, in the form of American Depositary Shares ("ADSs"), by the Highbridge Funds. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 09071M304 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Capital Market under the symbol "BLRX." Each ADS represents 600 Ordinary Shares. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172. Highbridge is a Delaware limited liability company. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 2,232,601,990 Ordinary Shares outstanding as of May 15, 2025, as reported in Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on May 23, 2025, and assumes the exercise of the warrants held by the Highbridge Funds. 7.2% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Ordinary Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Highbridge Capital Management, LLC /s/ Kirk Rule 08/14/2025